
Aribio achieved its primary endpoint in the global Phase 3 clinical trial of its "oral Alzheimer's drug" for the monotherapy group. In an Alzheimer's disease treatment market centered on injectable drugs, the confirmation of statistical significance for a treatment with the convenience of oral administration (a pill) as a monotherapy is considered encouraging.
On the 16th (local time), Aribio announced the results of the global Phase 3 clinical trial for its Alzheimer's disease drug candidate "AR1001" (generic name: mirodenafil) at the "International Conference on Alzheimer's Disease Clinical Trials" (CTAD 2026) held in Boston, United States. The presentation was delivered by Sharon Sha, a professor at Stanford University and the overall responsible clinician for AR1001's global Phase 3 trial.
Previously, Aribio conducted the global Phase 3 clinical trial (POLARIS-AD) on approximately 230 clinical trial sites across 13 countries, including the United States, Europe, South Korea, and China, enrolling 1,535 patients with early-stage Alzheimer's disease. The trial was completed after more than three years in July last month, and the data were disclosed for the first time at this year's CTAD.
Patients participating in the Phase 3 trial took one pill per day of either AR1001 30 milligrams (mg) or a placebo for 52 weeks and underwent regular clinical evaluations. The trial was designed to evaluate two pre-specified primary analysis populations, the full treatment population and the monotherapy population, in accordance with consultations with regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The results for both populations were analyzed according to a pre-defined multiplicity adjustment procedure. If a statistically significant difference is shown in one population, the primary endpoint is considered achieved.
The primary endpoint of this trial was the change from baseline in the "Clinical Dementia Rating Sum of Boxes" (CDR-SB) at Week 52. In the results for the 604th patients in the monotherapy group, the AR1001 treatment group showed a 31% delay in clinical deterioration compared to the placebo group. The adjusted mean difference between the treatment and placebo groups was −0.44 points (p=0.0266), which was statistically significant at the assigned significance level (α=0.03). The disease progression delay effect, converting the Week 52 CDR-SB results into time, was estimated at 3.5 months for the monotherapy group and 0.8 months for the full population.
However, the adjusted mean difference between the treatment and placebo groups among all 1,535 participants in the trial was −0.11 points (p=0.4015), which favored AR1001 numerically but was not statistically significant.
Aribio is expected to pursue new drug approval for AR1001 based on the efficacy results of the monotherapy group confirmed in the global Phase 3 clinical trial.